Thiruvananthapuram: Berry-bearing black nightshade bushes have been shown to have compounds that are useful for treating liver cancer.
Compound — uttroside-b — isolated from the factory as part of the ongoing research program from the Biotechnology Center of Rajiv Gandhi (RGCB) has been given as a (FDA) drug (FDA).
The ‘manhakcali’ leaves, eternal shrubs (Solanum Nigrum) are common in the backyard of the house and along the Kerala route, have a big properties to protect the largest internal organs of the human body from uncontrolled cell growth, the team of scientists with RGCB works in the project.
The appointment of ‘Orphan Children’s Medicine’ supports the development and evaluation of new care for rare diseases and allows fast approval of the drug.
The technology that was patented by Dr.
Ruby John Anto, a senior scientist at RGCB, and his student, Dr.
Lekshmi R Nath, has been purchased by the Pharma US company Qbiomed.
Technology transfer was carried out through the Oklahoma Medical Research Foundation, RGCB revealed here on Wednesday.
Dr.
Ruby and Dr.
Lekshmi isolated drug molecules, uttroside-b, from manhakcali leaves.
RGCB Director Dr.
Chandrabhas Narayana said this study had the potential to be a major breakthrough in the treatment of liver disease, including liver cancer.
The first milestone payment from Qbiomed has been received, he said.
“The findings are path-breaking, remembering the heart, which mainly detoxizes food while helping digestion, found increasingly susceptible to cancer in modern times.
Malignant diseases of the gall-producing organs are expected to kill no less than 800,000 people every year even as 900,000 new cases are reported every year year, “he said.
In collaboration with Dr.
L Ravishankar (CSIR-NIST, ThiruvananThapuram), which has developed a new method to isolate compounds from Solanum Nigrum leaves, Dr.
Ruby and the team are currently studying the efficacy of compounds against fatty liver disease, steatohepatitis and an alcoholic liver.
Cancer caused by food poisons.
Dr.
Ruby said at this time, there was only one FDA approved drug available for liver cancer treatment.
The compound developed by his team was found more effective than available, he said.
Evaluation of toxicity in human volunteers has shown that compounds are also effective in treating fatty livers.
The latest results from Labr Dr.
Ruby show that ChloroQuine phosphate, the drug used against malaria, if used in a combinatorial regimen with uttroside-b, can greatly increase the efficacy of uttroside-B therapy against liver cancer.
This technology has been given a patent by the US, Canada, Japan and South Korea.
Research work was published in journal groups, ‘scientific reports’.